GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 143, Issue , 2014, Pages 392-403

  Yu, Tenghua ^a   Liu, Manran ^b   Luo, Haojun ^c   Wu, Chengyi ^a   Tang, Xi ^b   Tang, Shifu ^b   Hu, Ping ^b   Yan, Yuzhao ^a   Wang, Zhiliang ^c   Tu, Gang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Estrogen GPER ERK signaling; GPER; Targeted therapy; Triple negative breast cancer

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CYCLIN A; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; G PROTEIN COUPLED ESTROGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN C FOS; PROTEIN KINASE B; TAMOXIFEN; UNCLASSIFIED DRUG; WORTMANNIN; ESTROGEN;

APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER STAGING; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; ENZYME ACTIVATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MOLECULARLY TARGETED THERAPY; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION; CELL MOTION; ENZYME IMMUNOASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETICS; GENOMICS; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL CULTURE; WESTERN BLOTTING; WOUND HEALING;

APOPTOSIS; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; ESTRADIOL; ESTROGENS; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; IMMUNOENZYME TECHNIQUES; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELLS, CULTURED; WOUND HEALING;

EID: 84903157420     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2014.05.003     Document Type: Article

References (45)

1. L.A. Carey, C.M. Perou, and C.A. Livasy et al. Race: breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 295 21 2006 2492 2502 (Pubitemid 43854964)
2. R. Dent, W.M. Hanna, and M. Trudeau et al. Pattern of metastatic spread in triple-negative breast cancer Breast Cancer Res. Treat. 115 2 2009 423 428
3. L.N. Harris, G. Broadwater, and N.U. Lin et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342 Breast Cancer Res. 8 6 2006 R66
4. K. Marie Significantly higher expression of vascular endothelial growth factor (VEGF) and shorter survival after recurrences in premenopausal node negative patients with triple negative breast cancer Cancer Res. 69 2 2009 128S 129S
5. C.K. Anders, E.P. Winer, and J.M. Ford et al. Poly(ADP-Ribose) polymerase inhibition: targeted therapy for triple-negative breast cancer Clin. Cancer Res. 16 19 2010 4702 4710
6. M.L. Telli, and J.M. Ford PARP inhibitors in breast cancer Clin. Adv. Hematol. Oncol. H&O 8 9 2010 629 635
7. K.P. Siziopikou, R. Ariga, and K.E. Proussaloglou et al. The challenging estrogen receptor-negative/progesterone receptor-negative/HER-2-negative patient: a promising candidate for epidermal growth factor receptor-targeted therapy? Breast J. 12 4 2006 360 362 (Pubitemid 43989982)
8. S. Nofech-Mozes, M. Trudeau, and H.K. Kahn et al. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers Breast Cancer Res. Treat. 118 1 2009 131 137
9. D.P. Pandey, R. Lappano, and L. Albanito et al. Estrogenic GPR30 signaling induces proliferation and migration of breast cancer cells through CTGF EMBO J. 28 5 2009 523 532
10. L. Albanito, D. Sisci, and S. Aquila et al. Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells Endocrinology 149 8 2008 3799 3808
11. M. Maggiolini, A. Vivacqua, and G. Fasanella et al. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17β-estradiol and phytoestrogens in breast cancer cells J. Biol. Chem. 279 26 2004 27008 27016 (Pubitemid 38812536)
12. A. Vivacqua, D. Bonofiglio, and A.G. Recchia et al. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17β-estradiol and hydroxytamoxifen in endometrial cancer cells Mol. Endocrinol. 20 3 2006 631 646 (Pubitemid 43291214)
13. C.M. Revankar, D.F. Cimino, and L.A. Sklar et al. A transmembrane intracellular estrogen receptor mediates rapid cell signaling Science 307 5715 2005 1625 1630 (Pubitemid 40354745)
14. E.J. Filardo, J.A. Quinn, and K.I. Bland et al. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog: GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF Mol. Endocrinol. 14 10 2000 1649 1660
15. L. Albanito, A. Madeo, and R. Lappano et al. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17β-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells Cancer Res. 67 4 2007 1859 1866 (Pubitemid 46383413)
16. A. Vivacqua, D. Bonofiglio, and L. Albanito et al. 17β-Estradiol: genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the G protein-coupled receptor GPR30 Mol. Pharmacol. 70 4 2006 1414 1423 (Pubitemid 44435994)
17. L.M. Luttrell, Y. Daaka, and R.J. Lefkowitz Regulation of tyrosine kinase cascades by G-protein-coupled receptors Curr. Opin. Cell Biol. 11 2 1999 177 183 (Pubitemid 29164031)
18. E.R. Prossnitz, J.B. Arterburn, and H.O. Smith et al. Estrogen signaling through the transmembrane G protein-coupled receptor GPR30 Annu. Rev. Physiol. 70 2008 165 190 (Pubitemid 351738176)
19. S. Fujiwara, Y. Terai, and H. Kawaguchi et al. GPR30 regulates the EGFR-Akt cascade and predicts lower survival in patients with ovarian cancer J. Ovarian Res. 5 1 2012 35-35
20. C.G. Bologa, C.M. Revankar, and S.M. Young et al. Virtual and biomolecular screening converge on a selective agonist for GPR30 Nat. Chem. Biol. 2 4 2006 207 212
21. E.J. Filardo, J.A. Quinn, and A.R. Frackelton et al. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis Mol. Endocrinol. 16 1 2002 70 84 (Pubitemid 34044499)
22. H. Luo, P. Luo, and G. Yang et al. G-protein coupled estrogen receptor 1 expression in primary breast cancers and its correlation with clinicopathological variables J. Breast Cancer 14 3 2011 185 190
23. G. Tu, D. Hu, and G. Yang et al. The correlation between GPR30 and clinicopathologic variables in breast carcinomas Technol. Cancer Res. Treat. 8 3 2009 231 234
24. E.J. Filardo, C.T. Graeber, and J.A. Quinn et al. Distribution of GPR30: a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression Clin. Cancer Res. 12 21 2006 6359 6366 (Pubitemid 44799705)
25. J. Steiman, E.A. Peralta, and S. Louis et al. Biology of the estrogen receptor: GPR30, in triple negative breast cancer Am. J. Surg. 206 5 2013 698 703
26. L. Wang, Y. Hou, and Y. Sun et al. c-Ski activates cancer-associated fibroblasts to regulate breast cancer cell invasion Mol. Oncol. 7 6 2013 1116 1128
27. M. Liu, M.C. Casimiro, and C. Wang et al. p21CIP1 attenuates Ras-and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo Proc. Natl. Acad. Sci. 106 45 2009 19035 19039
28. K. Milde-Langosch, A.M. Bamberger, and G. Rieck et al. Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer Br. J. Cancer 92 12 2005 2206 2215 (Pubitemid 40966259)
29. R. Dent, M. Trudeau, and K.I. Pritchard et al. Triple-negative breast cancer: clinical features and patterns of recurrence Clin. Cancer Res. 13 15 2007 4429 4434 (Pubitemid 47219710)
30. M. Tischkowitz, J.S. Brunet, and L.R. Bégin et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer BMC Cancer 7 1 2007 134
31. M. Aghili, M. Lashkari, and A. Hosein Farrokhpey et al. Triple-negative breast cancer survival in Iranian patients Acta Med. Iran. 51 8 2013 560 566
32. A. Madeo, and M. Maggiolini Nuclear alternate estrogen receptor GPR30 mediates 17β-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts Cancer Res. 70 14 2010 6036 6046
33. D. Wang, L. Hu, and G. Zhang et al. G protein-coupled receptor 30 in tumor development Endocrine 38 1 2010 29 37
34. L. Albanito, R. Lappano, and A. Madeo et al. G-protein-coupled receptor 30 and estrogen receptor-α are involved in the proliferative effects induced by atrazine in ovarian cancer cells Environ. Health Perspect. 116 12 2008 1648
35. K. Ohshiro, A.M. Schwartz, and P.H. Levine et al. Alternate estrogen receptors promote invasion of inflammatory breast cancer cells via non-genomic signaling PLoS ONE 7 1 2012 e30725
36. E.A. Ariazi, E. Brailoiu, and S. Yerrum et al. The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells Cancer Res. 70 3 2010 1184 1194
37. S. Broselid, B. Cheng, and M. Sjöström et al. G protein-coupled estrogen receptor is apoptotic and correlates with increased distant disease-free survival of estrogen receptor-positive breast cancer patients Clin. Cancer Res. 19 7 2013 1681 1692
38. E.W. LaPensee, T.R. Tuttle, and S.R. Fox et al. Bisphenol A at low nanomolar doses confers chemoresistance in estrogen receptor-α-positive and -negative breast cancer cells Environ. Health Perspect. 117 2 2009 175 180
39. M. Pupo, A. Pisano, and R. Lappano et al. Bisphenol A induces gene expression changes and proliferative effects through GPER in breast cancer cells and cancer-associated fibroblasts Environ. Health Perspect. 120 8 2012 1177 1182
40. T.J. Powles, S. Ashley, and A. Tidy et al. Twenty-year follow-up of the Royal Marsden randomized: double-blinded tamoxifen breast cancer prevention trial J. Natl. Cancer Inst. 99 4 2007 283 290 (Pubitemid 47073491)
41. P.E. Lonning Adjuvant endocrine treatment of early breast cancer Hematol. Oncol. Clin. North Am. 21 2 2007 223 238 (Pubitemid 46778800)
42. A. Ignatov, T. Ignatov, and A. Roessner et al. Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells Breast Cancer Res. Treat. 123 1 2010 87 96
43. A. Ignatov, T. Ignatov, and C. Weißenborn et al. G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer Breast Cancer Res. Treat. 128 2 2011 457 466
44. H. Luo, G. Yang, and T. Yu et al. GPER-mediated proliferation and estradiol production in breast cancer associated fibroblasts Endocrine-Related Cancer 21 2 2014 355 369
45. Z. Mo, M. Liu, and F. Yang et al. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer Breast Cancer Res. 15 6 2013 R114